Please login to the form below

Not currently logged in
Email:
Password:

Pfizer collaborates with US university

Pfizer and the University of California are to work together to accelerate drug discovery and development

Pfizer is to partner with San Diego Health Sciences, part of the University of California, through the company's Centers for Therapeutic Innovation (CTI) – a network of collaborative partnerships with top-tier life science research institutions in California, Massachusetts and New York – which aims to accelerate and transform drug discovery and development.

Pfizer anticipates a potential investment of up to $50m during the next five years to support the programmes and potential milestone payments to UC San Diego Health Sciences for successful projects. The partnership includes dedicated laboratory space at Pfizer's La Jolla research and development campus for scientists from Pfizer and UC San Diego Health Sciences to work together.

“The collaborative partnerships formed through the Centers for Therapeutic Innovation between Pfizer and academic medical centers allow leading medical and clinical experts to join with Pfizer's highly-skilled scientists and advanced drug development capabilities to speed the translation of innovative science into medicines for patients," said Dr Jose Carlos Gutierrez-Ramos, senior vice-president and head of biotherapeutics research and development for Pfizer. "Our ultimate goal is to bridge the gap between scientific discovery and the delivery of promising candidates to the pipeline,” he added.

Pfizer established its first CTI in California in November 2010 through a partnership with the University of California, San Francisco. Pfizer will expand its CTI West Coast presence to southern California through a collaboration with UC San Diego Health Sciences.

Additionally, Pfizer will provide funding to support the pre-clinical and clinical development of sponsored programmes, offer CTI partners equitable intellectual property rights and grant milestone payments and royalties related to the advancement of drug candidates.

9th August 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
wethepeople

wethepeople are bringing human appeal back to brand communications. Our approach allows us to create strategies, ideas and experiences that...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics